Ajanta Pharma Limited (NSE:AJANTPHARM)
2,931.00
+2.10 (0.07%)
Jun 1, 2026, 3:29 PM IST
Ajanta Pharma Revenue
In the fiscal year ending March 31, 2026, Ajanta Pharma had annual revenue of 54.53B INR with 17.31% growth. Ajanta Pharma had revenue of 14.22B in the quarter ending March 31, 2026, with 21.47% growth.
Revenue
54.53B
Revenue Growth
+17.31%
P/S Ratio
6.71
Revenue / Employee
5.66M
Employees
9,628
Market Cap
366.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 54.53B | 8.05B | 17.31% |
| Mar 31, 2025 | 46.48B | 4.39B | 10.44% |
| Mar 31, 2024 | 42.09B | 4.66B | 12.45% |
| Mar 31, 2023 | 37.43B | 4.02B | 12.02% |
| Mar 31, 2022 | 33.41B | 4.51B | 15.62% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Glenmark Pharmaceuticals | 174.43B |
| Alkem Laboratories | 147.12B |
| Ipca Laboratories | 98.21B |
| Emcure Pharmaceuticals | 92.04B |
| Piramal Pharma | 88.69B |
| Laurus Labs | 68.13B |
| Gland Pharma | 64.31B |
| NATCO Pharma | 40.78B |
Ajanta Pharma News
- 26 days ago - Pharma sector stocks rises today, May 6: Wockhardt jumps 7.16%, Ajanta Pharma surges 3.56%, Lupin up 1.60% - Business Upturn
- 27 days ago - Ajanta Pharma Transcript: Q4 25/26 - Transcripts
- 27 days ago - Ajanta Pharma Slides: Q4 2026 - Filings
- 27 days ago - Ajanta Pharma Quarterly report: Q4 2026 - Filings
- 27 days ago - Ajanta Pharma announces re-appointment of auditors for FY 2026-27 - Business Upturn
- 27 days ago - Ajanta Pharma grants 1,45,000 stock options and cancels 850 under ESOP plan - Business Upturn
- 27 days ago - Ajanta Pharma Q4 Results: Revenue jumps 21.5% YoY to Rs 1,421.64 crore, net profit up 18.4% - Business Upturn
- 5 weeks ago - Ajanta Pharma receives five observations from US FDA after facility inspection - Business Upturn